Federico Albrecht, MD
Hematology & Oncology · Miami, FLNPI 1366439689
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $70,203 of the $109,595 with a category attached, or 64.1%. 24 manufacturers reported payments, led by Boehringer Ingelheim at 31.0% of the total. Reporting peaked in 2019 at $30,874 and has fallen 53.2% since, to $14,440 in 2025. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $526.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$34K
- Lilly USA, LLC$23K
- Jazz Pharmaceuticals Inc.$15K
- Merck$9K
- E.r. Squibb & Sons, L.L.C.$9K
- Regeneron Healthcare Solutions, Inc.$8K
- plus $11K from 18 others
Across 5 payments — averaging $2749.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$13K
- Eli Lilly$500
What the payments were for
- Consulting fees$22,00420%
- Speaking & faculty fees$70,20364%
- Travel & lodging$10,2169%
- Food & beverage$7,1377%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 37 | $34,018 |
| Lilly USA, LLC | 26 | $22,672 |
| Jazz Pharmaceuticals Inc. | 17 | $15,328 |
| Merck | 18 | $9,430 |
| E.r. Squibb & Sons, L.L.C. | 34 | $9,081 |
| Regeneron Healthcare Solutions, Inc. | 14 | $8,169 |
| Partner Therapeutics, Inc. | 9 | $3,320 |
| Sanofi | 1 | $1,824 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Janssen Scientific Affairs, LLC | 4 | $1,214 |
| AstraZeneca | 15 | $745 |
| EMD Serono, Inc. | 2 | $624 |
| Daiichi Sankyo Inc. | 6 | $261 |
| Novocure Inc. | 5 | $246 |
| Array Biopharma Inc | 8 | $208 |
| Johnson & Johnson | 3 | $168 |
| Eagle Pharmaceuticals, Inc. | 1 | $149 |
| Coherus Oncology, Inc. | 1 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Mirati Therapeutics, Inc. | 1 | $123 |
| Amgen | 1 | $122 |
| Nuvation Bio Inc. | 1 | $76 |
| Rigel Pharmaceuticals, Inc. | 1 | $33 |
| Bayer | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$109,595 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 146 | $2,474,214 |
| AlecensaAlectinib Hcl | 22 | $414,456 |
| TabrectaCapmatinib Hydrochloride | 14 | $363,596 |
| GilotrifAfatinib Dimaleate | 25 | $330,442 |
| LorbrenaLorlatinib | 15 | $297,195 |
| AlunbrigBrigatinib | 11 | $220,686 |
| LumakrasSotorasib | 11 | $206,155 |
| MekinistTrametinib Dimethyl Sulfoxide | 13 | $197,188 |
| TafinlarDabrafenib Mesylate | 13 | $185,620 |
| EliquisApixaban | 30 | $20,739 |
| Erlotinib Hcl | 15 | $3,125 |
| Megestrol Acetate | 31 | $3,024 |
| Dexamethasone | 81 | $1,137 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 83 | $1,036 |
| Folic Acid | 108 | $671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $745 | $2,474,214146 claims |
| Boehringer IngelheimGilotrif | $34,018 | $330,44225 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Alunbrig | $125 | $220,68611 claims |
| AmgenLumakras | $122 | $206,15511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.